X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-04-02 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | Pres, 10% | P - Purchase | $6.14 | +25,000 | 7,537,140 | 0% | +$153,398 | |||||
2026-04-06 | ALKS | Alkermes Plc. | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S - Sale | $34.57 | -2,034 | 233,592 | -1% | -$70,315 | ||||||
2026-04-06 | LPCN | Lipocine Inc. | Higuchi John W. | Dir | P - Purchase | $2.05 | +123,000 | 163,797 | +301% | +$252,150 | ||||||
2026-04-06 | LPCN | Lipocine Inc. | Patel Mahesh V. | CEO | P - Purchase | $2.03 | +25,000 | 160,679 | +18% | +$50,750 | ||||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $4.93 | -1,772 | 96,136 | -2% | -$8,736 | |||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Thompson Travis Alvin | CFO | S - Sale | $4.93 | -901 | 65,364 | -1% | -$4,438 | |||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Perry Jennifer Scott | COO | S - Sale | $4.94 | -1,408 | 92,464 | -1% | -$6,962 | |||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Lee Kevin | CEO | S - Sale | $4.94 | -7,683 | 611,313 | -1% | -$37,964 | |||||
| M | 2026-04-02 | BCYC | Bicycle Therapeutics Plc | Skynner Michael | CHIEF SCIENTIFIC OFFICER | S - Sale | $4.94 | -2,404 | 159,562 | -1% | -$11,877 | |||||
2026-04-06 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale | $13.43 | -4,170 | 154,554 | -3% | -$56,014 | ||||||
2026-04-02 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.81 | -24,925 | 401,891 | -6% | -$119,889 | ||||||
2026-04-02 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $67.99 | -829 | 79,115 | -1% | -$56,364 | ||||||
| D | 2026-04-02 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $561.37 | -9,500 | 679,872 | -1% | -$5,333,053 | |||||
| D | 2026-04-02 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $561.50 | -10,000 | 18,876 | -35% | -$5,614,984 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Burns James William | GC | S - Sale+OE | $34.71 | -3,280 | 49,306 | -6% | -$113,849 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | $34.71 | -2,940 | 80,277 | -4% | -$102,047 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Jones Cecilia | CFO | S - Sale+OE | $34.71 | -3,141 | 54,998 | -5% | -$109,024 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Milanova Tsveta | Chief Commercial Officer | S - Sale+OE | $34.71 | -3,262 | 46,829 | -7% | -$113,224 | |||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Viswanadhan Krishnan | Chief Corp Dev, Strategy | S - Sale+OE | $34.71 | -2,959 | 10,282 | -22% | -$102,707 | |||||
2026-04-06 | ALT | Altimmune, Inc. | Gill John | Dir | P - Purchase | $3.41 | +9,200 | 21,700 | +74% | +$31,350 | ||||||
| D | 2026-04-02 | AGIO | Agios Pharmaceuticals, Inc. | Goff Brian | CEO | S - Sale+OE | $34.71 | -19,068 | 184,508 | -9% | -$661,850 | |||||
2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | CEO | S - Sale | $49.33 | -15,000 | 627,540 | -2% | -$739,912 | ||||||
| D | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Officer | S - Sale+OE | $50.00 | -7,958 | 0 | -100% | -$397,900 | |||||
| D | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | CFO | S - Sale+OE | $49.34 | -7,500 | 97,994 | -7% | -$370,076 | |||||
2026-04-02 | IMNM | Immunome Inc. | Higgins Jack | Chief Scientific Officer | S - Sale | $21.64 | -9,438 | 25,000 | -27% | -$204,238 | ||||||
| D | 2026-04-02 | IMNM | Immunome Inc. | Rosett Max | CFO | S - Sale+OE | $21.92 | -65,000 | 54,037 | -55% | -$1,424,916 | |||||
| D | 2026-04-02 | WHWK | Whitehawk Therapeutics, Inc. | Lennon David James | CEO | S - Sale+OE | $3.48 | -26,858 | 793,549 | -3% | -$93,466 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | S - Sale+OE | $20.39 | -9,614 | 120,619 | -7% | -$196,029 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale+OE | $20.39 | -4,194 | 24,590 | -15% | -$85,516 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Du Ying | Chairperson, CEO | S - Sale+OE | $20.39 | -5,576 | 1,125,279 | 0% | -$113,695 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $20.39 | -5,199 | 32,558 | -14% | -$106,008 | |||||
| D | 2026-04-02 | ZLAB | Zai Lab Ltd | Amado Rafael | See Remarks | S - Sale+OE | $20.39 | -9,910 | 59,761 | -14% | -$202,065 | |||||
2026-04-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $23.88 | -10,000 | 39,744 | -20% | -$238,801 | ||||||
2026-04-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | See Remarks | S - Sale | $5.99 | -16,667 | 1,209,840 | -1% | -$99,859 | ||||||
2026-04-01 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale | $69.04 | -52,003 | 62,874 | -45% | -$3,590,243 | ||||||
2026-04-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $190.50 | -6,000 | 384,682 | -2% | -$1,143,010 | ||||||
2026-04-02 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $2.10 | +713,800 | 3,511,896 | +26% | +$1,498,980 | ||||||
| D | 2026-04-02 | CAPR | Capricor Therapeutics, Inc. | Sabar Karimah Es | Dir | S - Sale+OE | $32.00 | -7,529 | 0 | -100% | -$240,928 | |||||
2026-04-01 | VRTX | Vertex Pharmaceuticals Inc / Ma | Liu Joy | EVP, GC | S - Sale | $449.17 | -978 | 21,833 | -4% | -$439,288 | ||||||
| D | 2026-04-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $105.21 | -11,430 | 85,533 | -12% | -$1,202,527 | |||||
2026-04-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $32.66 | -1,838 | 38,864 | -5% | -$60,029 | ||||||
2026-04-01 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | CFO | S - Sale | $18.64 | -5,727 | 125,373 | -4% | -$106,751 | ||||||
| D | 2026-04-01 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale+OE | $164.63 | -88,060 | 106,810 | -45% | -$14,497,651 | |||||
| D | 2026-04-01 | BIOA | Bioage Labs, Inc. | Rubin Paul D | Chief Medical Officer | S - Sale+OE | $17.81 | -8,820 | 0 | -100% | -$157,084 | |||||
2026-04-01 | EBS | Emergent Biosolutions Inc. | Williams Paul Anthony | SVP, Products Business | S - Sale | $8.44 | -4,000 | 62,681 | -6% | -$33,760 | ||||||
2026-04-01 | REGN | Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Dir | S - Sale | $777.27 | -100 | 17,603 | -1% | -$77,727 | ||||||
| M | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale | $16.96 | -15,959 | 17,338 | -48% | -$270,593 | |||||
| D | 2026-04-01 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $16.00 | -679 | 3,622 | -16% | -$10,864 | |||||
| D | 2026-04-01 | ERAS | Erasca, Inc. | Garner Ebun | GC | S - Sale+OE | $16.40 | -80,000 | 25,076 | -76% | -$1,312,000 | |||||
| D | 2026-04-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $21.20 | -27,000 | 112,622 | -19% | -$572,478 | |||||
| D | 2026-04-01 | IONS | Ionis Pharmaceuticals Inc | Klein Joseph III | Dir | S - Sale+OE | $75.55 | -22,321 | 11,114 | -67% | -$1,686,302 | |||||
2026-04-02 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale | $74.05 | -6,193 | 16,348 | -27% | -$458,613 | ||||||
2026-04-01 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $202.23 | -467 | 42,253 | -1% | -$94,440 | ||||||
2026-04-01 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $20.97 | -4,683 | 80,351 | -6% | -$98,203 | ||||||
2026-04-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Chief Medical Officer | S - Sale | $52.75 | -942 | 105,673 | -1% | -$49,693 | ||||||
2026-04-01 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $48.33 | -34,791 | 125,317 | -22% | -$1,681,512 | ||||||
| D | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $30.93 | -60,000 | 432,886 | -12% | -$1,855,839 | |||||
| D | 2026-04-01 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $30.00 | -10,000 | 105,211 | -9% | -$300,000 | |||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Neal James R | Dir | P - Purchase | $2.54 | +789 | 818 | >999% | +$2,000 | ||||||
2026-04-02 | LPCN | Lipocine Inc. | Patel Mahesh V. | CEO | P - Purchase | $2.02 | +25,000 | 135,679 | +23% | +$50,500 | ||||||
2026-03-31 | ZBIO | Zenas Biopharma, Inc. | Lu Hongbo | Dir | P - Purchase | $18.63 | +3,768 | 426,736 | +1% | +$70,198 | ||||||
2026-04-01 | TRDA | Entrada Therapeutics, Inc. | Wentworth Kory James | CFO | S - Sale | $12.95 | -2,500 | 119,010 | -2% | -$32,375 | ||||||
| D | 2026-04-02 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $565.87 | -8,300 | 45,172 | -16% | -$4,696,690 | |||||
| D | 2026-04-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $581.63 | -9,500 | 679,872 | -1% | -$5,525,526 | |||||
| D | 2026-03-31 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $585.76 | -9,500 | 679,872 | -1% | -$5,564,709 | |||||
2026-04-01 | BMY | Bristol Myers Squibb Co | Elkins David V | EVP, CFO | S - Sale | $61.67 | -30,000 | 159,542 | -16% | -$1,850,016 | ||||||
| D | 2026-04-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $32.31 | -28,662 | 9,597 | -75% | -$926,095 | |||||
2026-03-31 | KRRO | Korro Bio, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $10.60 | +520 | 1,538,296 | 0% | +$5,512 | ||||||
| D | 2026-04-01 | SCYX | Scynexis Inc | Angulo Gonzalez David | CEO | P - Purchase | $0.00 | +108,695 | 1,357,126 | +9% | +$0 | |||||
2026-03-30 | ANAB | Anaptysbio, Inc | Schmid John P. | Dir | S - Sale | $56.11 | -20,645 | 31,622 | -39% | -$1,158,451 | ||||||
| D | 2026-03-31 | CAPR | Capricor Therapeutics, Inc. | Krasney Karen | EVP, GC | S - Sale+OE | $30.12 | -25,000 | 30,547 | -45% | -$752,935 | |||||
| DM | 2026-03-31 | CAPR | Capricor Therapeutics, Inc. | Sabar Karimah Es | Dir | S - Sale+OE | $30.57 | -115,000 | 0 | -100% | -$3,515,468 | |||||
| D | 2026-03-31 | CAPR | Capricor Therapeutics, Inc. | Bergmann Anthony | CFO | S - Sale+OE | $30.13 | -25,000 | 8,223 | -75% | -$753,153 | |||||
| D | 2026-04-01 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $35.51 | -9,000 | 85,389 | -10% | -$319,604 | |||||
2026-03-30 | XERS | Xeris Biopharma Holdings, Inc. | Brady James Aloysius | Dir | S - Sale | $5.54 | -10,834 | 89,166 | -11% | -$60,036 | ||||||
| D | 2026-03-31 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | EVP, CFO, CBO | S - Sale+OE | $83.00 | -114,367 | 0 | -100% | -$9,492,596 | |||||
| D | 2026-03-31 | DNTH | Dianthus Therapeutics, Inc. /De/ | Soteropoulos Paula | Dir | S - Sale+OE | $80.11 | -599 | 0 | -100% | -$47,986 | |||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Pres Research, Development | P - Purchase | $2.54 | +1,810 | 12,978 | +16% | +$4,588 | ||||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Skibsted Russell | CFO | P - Purchase | $2.54 | +2,324 | 2,324 | New | +$5,891 | ||||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Pannu Geraldine | Dir | P - Purchase | $2.54 | +2,072 | 2,188 | >999% | +$5,253 | ||||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $2.54 | +2,136 | 7,937 | +37% | +$5,415 | ||||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $2.54 | +1,603 | 5,096 | +46% | +$4,064 | ||||||
2026-04-01 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.97 | -4,278 | 426,816 | -1% | -$21,262 | ||||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Chief Administrative Officer | P - Purchase | $2.54 | +1,854 | 3,443 | +117% | +$4,700 | ||||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Bigora Sian | Chief Development Officer | P - Purchase | $2.54 | +2,107 | 3,978 | +113% | +$5,341 | ||||||
2026-03-31 | PCSA | Processa Pharmaceuticals, Inc. | Baluch Khoso | Dir | P - Purchase | $2.54 | +2,269 | 2,325 | >999% | +$5,752 | ||||||
2026-04-01 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $66.63 | -7,500 | 426,996 | -2% | -$499,725 | ||||||
| D | 2026-03-30 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $97.81 | -5,500 | 58,117 | -9% | -$537,943 | |||||
2026-03-31 | ZBIO | Zenas Biopharma, Inc. | Fairmount Funds Management LLC | Dir | P - Purchase | $20.00 | +150,000 | 2,359,025 | +7% | +$3,000,000 | ||||||
2026-03-31 | CNTB | Connect Biopharma Holdings Ltd | Huang James | Dir | P - Purchase | $3.45 | +1,160,000 | 13,160,000 | +10% | +$4,002,000 | ||||||
2026-03-30 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $17.08 | +2,000 | 15,500 | +15% | +$34,160 | ||||||
2026-03-30 | PVLA | Palvella Therapeutics, Inc. | Jenkins George M | Dir | P - Purchase | $112.30 | +445 | 201,132 | 0% | +$49,974 | ||||||
2026-04-01 | ALT | Altimmune, Inc. | Weaver Gregory L | CFO | P - Purchase | $3.15 | +10,000 | 38,078 | +36% | +$31,499 | ||||||
2026-04-01 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Pres, CEO | P - Purchase | $3.14 | +15,000 | 47,500 | +46% | +$47,100 | ||||||
2026-03-31 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $12.62 | +5,000 | 24,007 | +26% | +$63,100 | ||||||
2026-03-31 | NSRX | Nasus Pharma Ltd | Teleman Dan Benjamin | CEO | P - Purchase | $2.04 | +15,000 | 21,246 | +240% | +$30,600 | ||||||
| D | 2026-03-31 | COGT | Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Dir | S - Sale+OE | $34.66 | -7,000,000 | 5,503,418 | -56% | -$242,620,000 | |||||
2026-03-31 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $4.38 | -29,985 | 1,430,423 | -2% | -$131,481 | ||||||
2026-03-27 | SLNO | Soleno Therapeutics Inc | Manning Meredith | Chief Commercial Officer | S - Sale | $30.44 | -7,522 | 64,507 | -10% | -$228,980 | ||||||
2026-03-27 | SLNO | Soleno Therapeutics Inc | Huang Michael F. | SVP of Clinical Development | S - Sale | $30.44 | -6,582 | 39,823 | -14% | -$200,365 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |